Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon van Engeland

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
A Four-Gene Promoter Methylation Marker Panel Consisting of <i>GREM1, NEURL, LAD1,</i> and <i>NEFH</i> Predicts Survival of Clear Cell Renal Cell Cancer PatientsIris J H van Vlodrop, Sophie C Joosten, Tim De Meyer, et al.
The Journal of Investigative Dermatology|August 1, 2025
Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical OutcomeKarin van den Hurk, Kim Lommen, Louis Coussement, et al.
Molecular Oncology|February 25, 2014
Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patientsMuriel X G Draht, Kim M Smits, Benjamin Tournier, et al.
Molecular Oncology|January 28, 2021
Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategiesLeonie K de Klerk, Ruben S A Goedegebuure, Nicole C T van Grieken, et al.
Cancer Research|May 14, 2009
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancerSabine C Glöckner, Mashaal Dhir, Joo Mi Yi, et al.
Oncotarget|October 4, 2017
<i>Decoy receptor 1</i> (<i>DCR1)</i> promoter hypermethylation and response to irinotecan in metastatic colorectal cancerLinda J W Bosch, Geert Trooskens, Petur Snaebjornsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancerDebby M E I Hellebrekers, Marjolein H F M Lentjes, Sandra M van den Bosch, et al.
Journal of the National Cancer Institute|June 19, 2009
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancerVeerle Melotte, Marjolein H F M Lentjes, Sandra M van den Bosch, et al.
Gastroenterology|September 1, 2024
Stool-Based Testing for Post-Polypectomy Colorectal Cancer Surveillance Safely Reduces Colonoscopies: The MOCCAS StudyBeatriz Carvalho, Willemijn de Klaver, Francine van Wifferen, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
A Four-Gene Promoter Methylation Marker Panel Consisting of <i>GREM1, NEURL, LAD1,</i> and <i>NEFH</i> Predicts Survival of Clear Cell Renal Cell Cancer PatientsIris J H van Vlodrop, Sophie C Joosten, Tim De Meyer, et al.
The Journal of Investigative Dermatology|August 1, 2025
Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical OutcomeKarin van den Hurk, Kim Lommen, Louis Coussement, et al.
Molecular Oncology|February 25, 2014
Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patientsMuriel X G Draht, Kim M Smits, Benjamin Tournier, et al.
Molecular Oncology|January 28, 2021
Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategiesLeonie K de Klerk, Ruben S A Goedegebuure, Nicole C T van Grieken, et al.
Cancer Research|May 14, 2009
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancerSabine C Glöckner, Mashaal Dhir, Joo Mi Yi, et al.
Oncotarget|October 4, 2017
<i>Decoy receptor 1</i> (<i>DCR1)</i> promoter hypermethylation and response to irinotecan in metastatic colorectal cancerLinda J W Bosch, Geert Trooskens, Petur Snaebjornsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancerDebby M E I Hellebrekers, Marjolein H F M Lentjes, Sandra M van den Bosch, et al.
Journal of the National Cancer Institute|June 19, 2009
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancerVeerle Melotte, Marjolein H F M Lentjes, Sandra M van den Bosch, et al.
Gastroenterology|September 1, 2024
Stool-Based Testing for Post-Polypectomy Colorectal Cancer Surveillance Safely Reduces Colonoscopies: The MOCCAS StudyBeatriz Carvalho, Willemijn de Klaver, Francine van Wifferen, et al.
Pageof 14